Source: Stanford Office of Technology Licensing. AI-generated summary by biochip.com, published . Not independently reviewed.
Key takeaways
- Arbabian Lab designed a microfluidic system that can analyze more than 100 parallel channels without scaling detection electronics.
- Functionalized interaction zones and impedance measurements aim to identify cells without chemical labeling.
- The concept is being tested with polystyrene beads and known cell lines, with error rates still under characterization.
Engineers in Professor Amin Arbabian's laboratory have built a microfluidics system intended to analyze large numbers of cells in blood while using far fewer electronic detection channels than a conventional parallel design. The lab-on-a-chip platform is designed for liquid biopsy, fetal cell analysis, whole-blood cell counting, and other cell-based tests. Its central idea is to divide a prepared blood sample across more than 100 tiny fluidic channels, then identify where a target cell traveled through shared electronics and signal-processing software. Each channel can also contain functionalized interaction zones that slow cells carrying particular surface biomarkers, creating a label-free way to distinguish cells. That could avoid the chemical labeling, or conjugation, step used in many cell-sorting workflows. The team is currently testing the concept with polystyrene beads and established cell lines while measuring its error rate with optical microscope monitoring. The detection instrument currently combines discrete integrated circuits with customized field-programmable gate array processing, rather than a fully miniaturized chip. If the system performs as intended at larger scale, it could offer a compact route to high-throughput single-cell analysis without multiplying the required electronics alongside every fluidic channel.
Making Many Channels Easier to Read
Microfluidics handles liquids in channels so small that they can direct and process individual cells. A useful analogy is a highway toll system: when hundreds of lanes need monitoring, installing a complete toll booth at every lane becomes expensive and crowded. The same bottleneck appears when a cell-analysis device sends blood through hundreds of parallel microchannels and tries to assign dedicated electronics to each one.
Arbabian's team addresses that problem with an electronics-sharing approach. The system assigns each microfluidic channel an effective ID number, then uses signal processing to decode the location of a target cell with a minimal number of electronic channels. This design aims to prevent the available chip area from being overwhelmed by detection hardware and to reduce interference among signals from densely packed channels.
How the Lab-on-a-Chip Handles Blood
The proposed workflow begins with a diluted blood sample entering the lab-on-a-chip. Smaller red blood cells and platelets are separated from larger white blood cells and circulating tumor cells, or CTCs, which are cancer cells that have entered the bloodstream. The remaining flow is then divided repeatedly through 1:2 fluidic splitters, producing a large array of parallel paths.
That parallelization matters because rare target cells may be scattered through a large population of ordinary blood cells. Instead of waiting for cells to pass through one narrow pathway, the system is designed to inspect many streams at once. After detection, selected cells could be sorted, collected, and sent to downstream methods such as fluorescence-activated cell sorting, known as FACS, or DNA sequencing.
Using Surface Markers Without Labels
The device is designed to identify cells through interaction zones, functionalized segments within each channel. Think of these zones as selective patches of Velcro: a cell that displays a matching surface feature encounters more resistance and takes longer to move through the channel. In this case, the relevant features are surface biomarkers, molecules on a cell that can help distinguish one cell type from another.
Electrodes positioned between interaction zones measure electrical impedance and cell transit time. Impedance measures how much a passing object resists an electrical signal, while transit time records how long the cell takes to cross a defined portion of the channel. Together, those measurements are intended to indicate both the cell's position and its interactions with the functionalized channel surfaces.
Why Label-Free Detection Could Help
Many conventional cell-sorting methods rely on conjugation, attaching a detectable label to a target cell through a chemical binding step. The proposed system instead seeks to use the cell's interaction with the channel and its electrical signature. Removing the labeling step could shorten a workflow and reduce the reagent costs associated with those added chemicals.
The team also expects surface-marker interactions to offer more specificity than sorting cells only by size. Size-based approaches can separate large and small cells, but cells of different biological types may overlap in size. A channel designed around multiple marker-sensitive interaction zones could, in principle, gather more distinguishing information from a single cell as it moves through the device.
Current Research Stage
The platform remains in early testing. The laboratory is evaluating the concept with polystyrene beads and known cell lines, not reported patient samples, while using optical microscope images to characterize the system's error rate. Those studies are aimed at determining whether the location-decoding method and the interaction-zone measurements can reliably identify the intended targets.
Its present instrumentation uses discrete integrated circuits and customized processing on a field-programmable gate array, or FPGA, a reconfigurable electronic chip used to process signals rapidly. The team expects the electronics could be further miniaturized with complementary metal-oxide-semiconductor, or CMOS, technology. CMOS is the common manufacturing approach used for many modern integrated circuits and could bring more of the electronics into a compact device format.
Potential Uses in Blood Testing
The platform's proposed applications include liquid biopsy, a test that examines material circulating in blood rather than requiring a tissue sample. The technology is positioned for detection of CTCs, circulating tumor DNA, or ctDNA, and exosomes, tiny particles released by cells, in cancer diagnostics and treatment monitoring. It is also intended for fetal-cell detection in maternal blood and for whole-blood cell counting.
For point-of-care testing, the appeal would be a system that can process cells rapidly in a smaller, potentially lower-cost format than a conventional flow cytometer. Flow cytometry is a widely used technique that moves cells past detectors to measure their physical and molecular characteristics. The shared-electronics architecture is the key design feature meant to make extensive parallel processing practical without matching every new channel with a new detector.
Why This Matters
Rare-cell analysis sits at the intersection of biology and engineering: the target may be important, but it can be outnumbered by billions of other cells. The lab's design tackles that challenge by combining physical separation, biomarker-sensitive flow resistance, and electrical readouts inside a massively parallelized microfluidic device. Rather than treating throughput, specificity, and compact electronics as separate problems, it attempts to address all three in one architecture.
The next important step is to move from bead and cell-line testing toward more demanding biological samples while continuing to quantify errors. Miniaturizing the electronics with CMOS technology could also determine how readily the shared-detection approach translates into a more integrated instrument. The platform's value will depend on whether its label-free measurements can maintain reliable cell identification as sample complexity and throughput increase.
Topics: Lab-on-a-chip · Microfluidics · Cancer · Diagnostics & precision medicine
Start here: Microfluidics explained